北京4例感染者基因測序結果公佈 爲同一傳播鏈
格隆匯4月24日丨在北京市新型冠狀病毒肺炎疫情防控工作第313場新聞發佈會上,北京市疾控中心副主任、全國新型冠狀病毒肺炎專家組成員龐星火介紹,北京市疾控中心對4月22日以來通報的感染者139、140、141、143的標本進行基因測序,結果顯示病毒均屬於奧密克戎變異株,4例感染者病毒序列完全一致,與近期京外聚集性疫情,以及外溢至其他省市的病毒序列完全一致。綜合流行病學調查及基因測序結果初步判斷,感染者140、141、143爲同一傳播鏈,感染者139流調溯源工作仍在進行中,感染來源還需結合流行病學調查進一步確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.